6 November 2020 

Celltrion announced safety and efficacy results from the Phase I clinical trial of CT-P59 on mild Covid-19 patients. The biopharmaceutical company announced these results at a recent conference of the Korean Society of Infectious Diseases and Korean Antimicrobial Therapeutics.

NeuroRx and Relief Therapeutics announced that the independent Data Monitoring Committee has voted for the full enrolment of 165 patients for the Phase IIb/III NCT 04311697 study.  The committee cited no issues with safety and believed that the study could reach its prespecified endpoint, proving that RLF-100 allows critical Covid-19 patients to achieve recovery from respiratory failure.

Arch Biopartners announced that it had begun dosing patients with its LSALT peptide drug in a Phase II trial in Turkey. The drug targets acute injury to the lungs, kidney, and other complications caused by inflammation among moderate to severely affected hospitalised Covid-19 patients.

The government of Bangladesh signed a memorandum of understanding with the Serum Institute of India (SII) and Bexmico Pharmaceuticals to procure 30 million doses of Covishield, a Covid-19 vaccine being developed by the University of Oxford, AstraZeneca and the SII. Once developed, five million doses of the vaccine will be purchased through Bexmico every month, according to the Health Minister.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.